LUZP6
Leucine zipper protein 6
Also known as: LUZP6_HUMAN
Protein identityUniProt · HPA
OverviewNCBI Gene
No narrative summary is available for LUZP6 in this catalog release; identity and structured annotations are shown without generated factual claims.
Canonical amino-acid sequenceUniProt
58 residues, UniProt reviewed canonical sequence.
>Q538Z0|LUZP6
1 MKSVISYALY QVQTGSLPVY SSVLTKSPLQ LQTVIYRLIV QIQHLNIPSS SSTHSSPFLocalizationUniProt · AlphaFold · HPA
Whether an antibody against LUZP6 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Unknown
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.5
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD missense Z
- 0
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 11% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads LUZP6 as an antibody target. Whether an autoantibody or antibody against LUZP6 could matter depends on whether native LUZP6 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
LUZP6 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label LUZP6 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...